FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001081617> ?p ?o ?g. }

• W2001081617 endingPage "359" @default.
• W2001081617 startingPage "349" @default.
• W2001081617 abstract "Apart from its repressing effect on plasma lipid levels, 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors exert neuroprotective functions in animal models of neurodegenerative disorders. In view of these promising observations, we were interested in whether HMG-CoA reductase inhibition would affect epileptiform activity in the brain. To elucidate this issue, atorvastatin, simvastatin and rosuvastatin were administered orally at a dose of 20 mg/kg each for 3 days and their anti-epileptic activities were tested and compared in rats. Epileptiform activity in the brain was induced by an intracortical penicillin G injection. Among HMG-CoA reductase inhibitors, simvastatin-treatment was less effective in terms of spike frequency as compared with atorvastatin- and rosuvastatin-treated animals. Atorvastatin treatment reduced spike frequencies and amplitudes significantly throughout the experiment. However, the most pronounced anti-epileptic effect was observed in rosuvastatin-treated animals, which was associated with improved blood-brain barrier (BBB) integrity, increased expression of endothelial nitric oxide synthase (eNOS) mRNA and decreased expressions of pro-apoptotic p53, Bax and caspase-3 mRNAs. Inhibition of eNOS activity with L-NG-Nitroarginine Methyl Ester (L-NAME) reversed the anti-epileptic effect of rosuvastatin significantly. However, L-NAME did not alter the effect of rosuvastatin on the levels of p53, Bax and caspase-3 mRNA expression. Here, we provide evidence that among HMG-CoA reductase inhibitors, rosuvastatin was the most effective statin on the reduction of epileptiform activity, which was associated with improved BBB permeability, increased expression of eNOS and decreased expressions of pro-apoptotic p53, Bax and caspase-3. Our observation also revealed that the anti-epileptic effect of rosuvastatin was dependent on the increased expression level of eNOS. The robust anti-epileptic effect encourages proof-of-concept studies with rosuvastatin in human epilepsy patients with hypercholesterolemia." @default.
• W2001081617 created "2016-06-24" @default.
• W2001081617 creator A5013141968 @default.
• W2001081617 creator A5021605414 @default.
• W2001081617 creator A5026416468 @default.
• W2001081617 creator A5048620128 @default.
• W2001081617 creator A5051871584 @default.
• W2001081617 creator A5061031765 @default.
• W2001081617 creator A5064504988 @default.
• W2001081617 creator A5073717767 @default.
• W2001081617 creator A5079692247 @default.
• W2001081617 creator A5086744826 @default.
• W2001081617 creator A5087490218 @default.
• W2001081617 date "2015-01-01" @default.
• W2001081617 modified "2023-10-17" @default.
• W2001081617 title "HMG-CoA reductase inhibitor rosuvastatin improves abnormal brain electrical activity via mechanisms involving eNOS" @default.
• W2001081617 cites W119798858 @default.
• W2001081617 cites W1532944255 @default.
• W2001081617 cites W1537398036 @default.
• W2001081617 cites W1545266136 @default.
• W2001081617 cites W1546258268 @default.
• W2001081617 cites W1783939843 @default.
• W2001081617 cites W1965387410 @default.
• W2001081617 cites W1970224993 @default.
• W2001081617 cites W1976520518 @default.
• W2001081617 cites W1990926703 @default.
• W2001081617 cites W1999142774 @default.
• W2001081617 cites W1999284260 @default.
• W2001081617 cites W2013105910 @default.
• W2001081617 cites W2013430162 @default.
• W2001081617 cites W2017885661 @default.
• W2001081617 cites W2022927857 @default.
• W2001081617 cites W2022981588 @default.
• W2001081617 cites W2031483215 @default.
• W2001081617 cites W2031550562 @default.
• W2001081617 cites W2040958998 @default.
• W2001081617 cites W2043449640 @default.
• W2001081617 cites W2047347875 @default.
• W2001081617 cites W2062539275 @default.
• W2001081617 cites W2065214055 @default.
• W2001081617 cites W2067462455 @default.
• W2001081617 cites W2070013537 @default.
• W2001081617 cites W2070383923 @default.
• W2001081617 cites W2071248867 @default.
• W2001081617 cites W2071624888 @default.
• W2001081617 cites W2075068003 @default.
• W2001081617 cites W2077589574 @default.
• W2001081617 cites W2081203120 @default.
• W2001081617 cites W2084604930 @default.
• W2001081617 cites W2092452930 @default.
• W2001081617 cites W2099508080 @default.
• W2001081617 cites W2106578597 @default.
• W2001081617 cites W2111779594 @default.
• W2001081617 cites W2112937635 @default.
• W2001081617 cites W2121280612 @default.
• W2001081617 cites W2127308229 @default.
• W2001081617 cites W2143108597 @default.
• W2001081617 cites W2148411133 @default.
• W2001081617 cites W2149239016 @default.
• W2001081617 cites W2164248223 @default.
• W2001081617 doi "https://doi.org/10.1016/j.neuroscience.2014.10.014" @default.
• W2001081617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25453767" @default.
• W2001081617 hasPublicationYear "2015" @default.
• W2001081617 type Work @default.
• W2001081617 sameAs 2001081617 @default.
• W2001081617 citedByCount "31" @default.
• W2001081617 countsByYear W20010816172017 @default.
• W2001081617 countsByYear W20010816172018 @default.
• W2001081617 countsByYear W20010816172019 @default.
• W2001081617 countsByYear W20010816172020 @default.
• W2001081617 countsByYear W20010816172021 @default.
• W2001081617 countsByYear W20010816172022 @default.
• W2001081617 countsByYear W20010816172023 @default.
• W2001081617 crossrefType "journal-article" @default.
• W2001081617 hasAuthorship W2001081617A5013141968 @default.
• W2001081617 hasAuthorship W2001081617A5021605414 @default.
• W2001081617 hasAuthorship W2001081617A5026416468 @default.
• W2001081617 hasAuthorship W2001081617A5048620128 @default.
• W2001081617 hasAuthorship W2001081617A5051871584 @default.
• W2001081617 hasAuthorship W2001081617A5061031765 @default.
• W2001081617 hasAuthorship W2001081617A5064504988 @default.
• W2001081617 hasAuthorship W2001081617A5073717767 @default.
• W2001081617 hasAuthorship W2001081617A5079692247 @default.
• W2001081617 hasAuthorship W2001081617A5086744826 @default.
• W2001081617 hasAuthorship W2001081617A5087490218 @default.
• W2001081617 hasConcept C104950815 @default.
• W2001081617 hasConcept C126322002 @default.
• W2001081617 hasConcept C134018914 @default.
• W2001081617 hasConcept C134651460 @default.
• W2001081617 hasConcept C181199279 @default.
• W2001081617 hasConcept C185592680 @default.
• W2001081617 hasConcept C25498285 @default.
• W2001081617 hasConcept C2776329913 @default.
• W2001081617 hasConcept C2776839432 @default.
• W2001081617 hasConcept C2777320049 @default.
• W2001081617 hasConcept C2777482532 @default.
• W2001081617 hasConcept C2777622882 @default.
• W2001081617 hasConcept C2778326061 @default.

• next